Skip to main content

ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · IEX Real-Time Price · USD
21.32 1.92 (9.90%)
Dec 7, 2021 4:00 PM EST - Market closed
Market Cap3.43B
Revenue (ttm)474.39M
Net Income (ttm)-191.54M
Shares Out160.76M
EPS (ttm)-1.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,725,392
Open21.80
Previous Close19.40
Day's Range19.81 - 21.86
52-Week Range15.68 - 57.34
Beta0.57
AnalystsBuy
Price Target25.11 (+17.8%)
Earnings DateNov 8, 2021

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive a...

IndustryBiotechnology
IPO DateMay 27, 2004
CEOStephen Davis
Employees570
Stock ExchangeNASDAQ
Ticker SymbolACAD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 25.11, which is an increase of 17.78% from the latest price.

Price Target
$25.11
(17.78% upside)
Analyst Consensus: Buy

News

Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.

Other symbols:CLLSNTLANVAX
4 hours ago - Stockmarketcom

ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study

ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.

5 hours ago - Zacks Investment Research

Why Acadia Pharmaceuticals Stock Is Rocketing Today

A positive clinical readout is lighting a fire underneath the biotech's shares today.

10 hours ago - The Motley Fool

Acadia Pharma Jumps After Rett Syndrome Candidate Aces Phase 3 Study

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a statistically significant improvement ov...

12 hours ago - Benzinga

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety of trofineti...

1 day ago - Business Wire

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week,...

6 days ago - Business Wire

Why Seasoned Investors are Retaining Acadia (ACHC) Stock

Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.

1 week ago - Zacks Investment Research

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to B...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the national launch of Yours, Truly, a multicultural, storytelling campaign to bring greater awareness and understa...

3 weeks ago - Business Wire

ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates.

4 weeks ago - Zacks Investment Research

Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021. “Our third-quarter results reflect volume gr...

4 weeks ago - Business Wire

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) ou...

1 month ago - Business Wire

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective...

1 month ago - Business Wire

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. f...

1 month ago - Business Wire

4 Healthcare Stocks to Top Q3 Estimates Amid Coronavirus Woes

Factors like an aging populace and demand for products and services are likely to reflect on the Q3 results of ACAD, MD, ACHC and VRTX.

1 month ago - Zacks Investment Research

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson's Disease Dementia with Psychosis f...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with P...

1 month ago - Business Wire

3 Biotech Stocks to Watch Now

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

Other symbols:FATEPIRS
1 month ago - Benzinga

Can These Former Biotech Growth Stocks Regain Their Form?

Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.

Other symbols:CLVS
2 months ago - The Motley Fool

Here's Why You Should Buy Acadia Healthcare (ACHC) Stock Now

Acadia Healthcare (ACHC) continues to gain from top-line growth, solid demand for behavioral health services, several growth-related initiatives and reducing debt levels.

Other symbols:ACHC
2 months ago - Zacks Investment Research

Acadia (ACAD) Down 10.8% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 16th Annual BioPharma Virtual Confe...

3 months ago - Business Wire

Acadia Pharmaceuticals Announces Executive Leadership Change

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effecti...

3 months ago - Business Wire

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Other symbols:ABCLFOLDSRPTTGTX
3 months ago - The Motley Fool

Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p...

4 months ago - Business Wire